Medtronic completes SPR Therapeutics acquisition
Medtronic bought the pain company to expand in neuromodulation, one of its areas of strategic focus and investment.
Medtronic completes SPR Therapeutics acquisition Read More »
Medtronic bought the pain company to expand in neuromodulation, one of its areas of strategic focus and investment.
Medtronic completes SPR Therapeutics acquisition Read More »
Venture capital funding deals worth $100 million or more made up nearly half of all money invested so far this year, according to Rock Health.
Large funding rounds help boost digital health investment in H1 Read More »
The Senate voted along party lines Thursday to defeat Democrats’ attempt to end WISeR, which they argue is delaying care for seniors.
Senate Republicans kill bid to end Medicare prior authorization pilot Read More »
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
2026 IPO stock tracker: How biotechs new to public markets are performing Read More »
Structural gaps in areas including clinical execution and funding limit India’s ability to scale up innovation, according to a report from Boston Consulting Group and HealthKois.
India’s life sciences sector at turning point for innovation: Report Read More »
Hay momentos en la historia de la ciencia en los que cambia el objeto de estudio, y momentos mucho más escasos en los que cambia la propia forma de estudiar. Llevo años siguiendo de cerca la intersección entre la inteligencia artificial y la investigación cien …
Inteligencia artificial en la ciencia: los avances que marcarán 2026 Read More »
Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail Read More »
Journal publications that suggested changes in FDA guidelines do not “communicate FDA policy or interpretation of a regulatory issue,” acting director Kyle Diamantas wrote in a letter to House Energy & Commerce committee ranking member Diana DeGette.
Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability Read More »
Por un instante, deje de mirar la pantalla. Mire a su alrededor. La mesa, la taza de café, la ventana… todo parece seguir ahí, imperturbable, ocupando un lugar exacto en el espacio. El sentido común nos dice que el universo físico posee propiedades bien definidas, nos f …